Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses

Biotech Giants' Cost Evolution: Halozyme vs. Veracyte

__timestampHalozyme Therapeutics, Inc.Veracyte, Inc.
Wednesday, January 1, 20142273200016606000
Thursday, January 1, 20152924500021497000
Friday, January 1, 20163320600025462000
Sunday, January 1, 20173115200028195000
Monday, January 1, 20181013600033078000
Tuesday, January 1, 20194554600036523000
Wednesday, January 1, 20204336700041455000
Friday, January 1, 20218141300074400000
Saturday, January 1, 2022139304000101582000
Sunday, January 1, 2023192361000112903000
Monday, January 1, 2024159417000
Loading chart...

Cracking the code

Cost Insights: Halozyme Therapeutics, Inc. vs. Veracyte, Inc.

In the ever-evolving landscape of biotechnology, understanding the financial dynamics of key players is crucial. This analysis delves into the cost structures of Halozyme Therapeutics, Inc. and Veracyte, Inc. over the past decade. From 2014 to 2023, Halozyme's cost of revenue surged by an impressive 747%, peaking at $192 million in 2023. In contrast, Veracyte's expenses grew by 580%, reaching $113 million in the same year. Notably, both companies experienced significant growth in 2021, with Halozyme's costs increasing by 88% and Veracyte's by 80% compared to the previous year. This trend highlights the increasing operational demands and investments in innovation within the biotech sector. As these companies continue to expand, stakeholders must keep a keen eye on their financial strategies to gauge future performance.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025